

# Alizin 30 mg/ml Solution for Injection

Authorised

- Aglepristone

## Product identification

**Medicine name:**

Alizin 30 mg/ml Solution for Injection  
Alizin 30 mg/ml Oplossing voor injectie  
Alizin 30 mg/ml Solution injectable  
Alizin 30 mg/ml Injektionslösung

**Active substance:**

Aglepristone

**Target species:**

Dog

**Route of administration:**

Subcutaneous use

## Product details

**Active substance and strength:**

Aglepristone  
30.00 milligram(s) / 1.00 millilitre(s)

**Pharmaceutical form:**

Solution for injection

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QG03XB90

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Belgium

---

**Available in:**

Belgium

---

**Package description:**

Vial (glass, type II) of 5 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation:- box of 1 vial of 5ml

Vial (glass, type II) of 10 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation:- box of 1 vial of 10ml.

Vial (glass, type II) of 30 ml for injectable preparation, with bromobutyl stopper and aluminum cap. Presentation:- box of 1 vial of 30ml.

Vials (glass, type II) of 10 ml for injectable preparations, with bromobutyl stoppers and aluminum caps. Presentation:- box of 10 vials of 10ml.

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Full application (Article 12(3) of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Virbac

---

**Marketing authorisation date:**

14/06/2004

---

**Manufacturing sites for batch release:**

Virbac

---

**Responsible authority:**

Federal Agency For Medicines And Health Products

---

**Authorisation number:**

BE-V263986

---

**Date of authorisation status change:**

14/06/2004

---

**Reference member state:**

Ireland

---

**Procedure number:**

IE/V/0500/001

---

**Concerned member states:**

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland  
Germany Greece Hungary Iceland Italy Latvia Lithuania Luxembourg  
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain  
Sweden United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Summary of Product Characteristics

English (PDF)

Published on: 16/11/2025

Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents